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Recent trends in Molecular Imaging :
PET/CT in Neurology
PET/CT is an important molecular imaging technique for the assessment of 
neurological disorders. The most widely used radiopharmaceutical for both clinical 
and research purposes is [18F] 2-ﬂuoro-2-deoxy-D-glucose (FDG). It is extensively 
used owing to its favourable physical characteristics. It enables depiction of cerebral 
glucose metabolism, and has thus been used to study various pathological states. 
Despite this, FDG has its own limitations. This is owing to its limited speciﬁcity and 
high cortical uptake. This has paved the way for the development of several non-FDG 
PET radiopharmaceuticals. We present the insights gained at our institution, using 
these radiotracers in the assessment of neurological disease. Our study shows that the 
use of FDG and non-FDG novel PET radiopharmaceuticals facilitates the early 
diagnosis, delineation of extent, prognostication and monitoring of therapeutic 
response in several neuropathological states.
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Introduction
 The ﬁrst oncological application 
of PET was in the assessment of brain 
tumors (1).  In general, PET/CT using 
FDG has gained widespread acceptance in 
tumor evaluation owing to its ability to 
detect tumors and deﬁne their extent, 
provide information that aids planning of 
radiotherapy and operative interventions, 
show response to treatment, and detect 
tumor recurrence. FDG has been aptly 
called the molecule of the millennium 
owing to i ts  profound impact on 
oncological imaging. However, FDG may 
not be an ideal imaging agent for brain 
tumors as there is a high physiological 
g lucose  up take  in  no rma l  b ra in 
parenchyma, glucose being an obligatory 
energy substrate for brain. This leads to 
intense radiotracer uptake in normal brain 
tissue (2), and, as a result, low grade 
tumors, small tumors, and tumors with 
early recurrence may go undetected. 
Moreover, FDG uptake is relatively 
nonspeciﬁc and is seen to occur in 
inﬂammatory and granulomatous tissues 
also (3).
 A h o s t  o f  n o n - F D G  P E T 
radiotracers with oncological applications 
have been developed. These include 
radiotracers for amino acid synthesis, 
Deoxyribonucleic acid (DNA) synthesis, 
lipid synthesis, hypoxia, angiogenesis, 
and peptide receptors.
 Each of these has their inherent 
strengths and limitations, a detailed 
understanding of which is a pre-requisite 
to their optimal utilization.
 One of the most  important 
neurological application of PET imaging 
is in the work-up of the dementia patient 
(4). It serves as a useful aid to enable an 
accurate diagnosis as early in the course of 
the disease as possible. It also aids in 
differentiating the different forms of 
dementia on the basis of pattern of FDG 
uptake in different parts of the brain 
parenchyma. Further, it facilitates the 
determination of the course and severity 
of the disease. FDG PET/CT is also 
proving useful in the detection of cases 
with MCI (mild cognitive impairment). 
The early diagnosis and response to 
therapeutic intervention is an area of 
intense research today.
 Movement disorders, namely 
Parkinson's Disease and Parkinsonian 
Syndromes can be assessed using 
PET/CT.  Based on the differential pattern 
of uptake of FDG in various disorders, the 
various subgroups of movement disorders 
can be distinguished. Further, PET 
imaging with 18F-ﬂuorodopa has been 
performed to evaluate the presynaptic 
dopaminergic function, and has shown 
abnormalities in the nigro-striatal 
projection (5). 18F-ﬂuorodopa studies 
have been used in early diagnosis,  
investigation of clinical course and the 
effects of therapy in patients with 
movement disorder. Imaging with 
postsynaptic dopamine receptor tracers 
has also been undertaken, to assess the 
pathogenesis and course of the disease. 
 Other important areas where 
PET/CT plays an important role is 
cerebrovascular disease (haemorrhaﬁc or 
ischemic), seizures, brain trauma etc. 
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Material and Methods 
 The study comprised of 286 
patients with neurological disease. Of 
these, there were 117 subjects with 
dementia 104 subjects with movement 
disorders and 65 subjects with brain 
tumors. All patients underwent an FDG 
PET scan. Of the 286 patients, 153 
number of cases further underwent 
s c a n n i n g  u s i n g  n o n - F D G  n o v e l 
radiotracers. All participants provided 
written informed consent. 
 For the FDG PET study, all 
subjects were fasting for at least 4 hours 
prior to the study. The study was 
performed in a resting state with eyes 
closed. It was performed on a Discovery 
STE 16(GE) camera. A dose of 370 MBq 
of FDG was injected intravenously and a 
brain scan was obtained after an interval 
of 60 minutes, with patient in supine 
position and head immobilized in a head 
rest. An initial scout was followed by a 
low dose CT acquisition. This was 
followed by a static 20 minute single bed 
position 3-dimensional emission scan. 
Reconstructed data was viewed on a 
Xeleris work-station. Data acquisition 
was performed along similar lines for 
other non-FDG PET tracers, with 
modiﬁcation of dose and post-injection 
wait ing period depending on the 
individual radiopharmaceutical, eg. 550-
740 MBq of 11C-methionine with 20 
minute delay post-injection.
 Data analysis was performed by 
visual image interpretation using plain 
PET, CT and fused PET/CT images. 
Semiquantitative assessment using 
SUVmax was also performed in those 
cases where a lesion was localizable. SUV 
(s tandardized uptake value)  is  a 
semiquantitative numerical value which 
normalizes the lesion uptake to injected 
dose per unit body weight.  The same 
procedure was performed for both FDG 
and non-FDG PET procedures.
Results
 The patients evaluated on PET/CT 
could be broadly categorized into 3 large 
subsets : brain tumor, cases of dementia 
and movement disorder.
Brain Tumors :
 A total of 97 patients with 
intraparenchymal brain tumor was 
as sessed .  Of  these ,  h i s to log ica l 
conﬁrmation was possible in 65 cases.  Of 
these 65 subjects with brain tumor, there 
were 18 newly diagnosed cases and 47 
previously treated cases.  FDG PET/CT 
was performed in all cases, while 11C-
methionine scan was performed in 45 
cases, F-DOPA (3,4-dihydroxy-6-18F-
ﬂuoro-L-phenylalanine) scan was 
performed in 20 cases,  FLT (18-
ﬂuorothymidine) in 19 cases, FMISO 
(18F-misonidazole) scan in 3 cases and 
FET (O-(2-[18F]ﬂuoroethyl)-l-tyrosine ) 
in 2 cases.
 11C-methionine was found to be 
more efﬁcacious than FDG PET/CT both 
for the primary detection of tumor and 
delineation of its extent (ﬁg.1). It was 
useful in distinguishing tumorous from 
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non-tumorous lesions. It showed selective 
uptake in neoplastic tissue, and was thus 
useful in assessing the size and margins of 
the lesion. This was applicable both for 
primary tumors and post-treatment cases 
as well. Low grade gliomas were also 
better depicted on 11C-methionine 
PET/CT. In case of recurrent brain tumors, 
it was superior to FDG not just in the 
delineation of the area of recurrence, but 
also in the detection of secondary 
deposits. Also, interobserver variability in 
interpretation was less on 11C-methionine 
compared to FDG.
 F-DOPA was extremely sensitive 
in picking up both primary and recurrent 
lesions (ﬁg.2). It scored over FDG in the 
evaluation of all types of brain tumors, but 
most signiﬁcantly in the case of low-grade 
gliomas. It was positive in all cases of 
primary and recurrent low grade gliomas 
and negative in patients with remission.
 FLT exhibited high sensitivity and 
speciﬁcity in case of high grade gliomas. 
However, it  faired suboptimally in case of 
low grade gliomas – both in case of 
primary and recurrent tumors.  FMISO 
was sensitive in picking up areas of 
recurrence, and showed areas of tumor 
hypoxia. The limited study performed 
using FET also showed it to be superior to 
FDG in delineation of tumor extent.
Mild cognitive impairment (MCI) and 
Dementia:
 Of the 117 subjects included with 
neurocognitive deﬁcits, there were 39 
patients with MCI, 40 with Alzheimer's 
Disease (AD), 14 with Fronto-temporal 
Dementia (FTD), 13  with Diffuse Lewy 
Body Dementia (DLBD) and 11 with 
dementia due to miscellaneous causes. 
FDG PET/CT was performed in all 
patients. All patients were followed up 
clinically for a period of at least one year.  
MCI patients showed reduced tracer 
uptake primarily in the mesiotemporal 
cortex, AD patients in the temporoparietal 
lobes with advanced cases showing 
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Fig.1 :  A post-operative case of grade II glioma. 
FDG PET/CT image (A) shows no area of 
increased uptake at the operative site s/o negative 
study. However, 11C-methionine scan (B) clearly 
shows recurrence in the right temporal region 
(arrow).
Fig.2 :  A post-operative case of recurrent 
glioma. Lesion delineation is superior on F-DOPA 
PET/CT image (A) compared to the  FDG PET/CT 
image (B).
frontal lobe involvement as well (ﬁg.3), 
FTD cases in the frontotemporal lobes 
(ﬁg.4), while DLBD showed global 
reduction in  tracer uptake including the 
occipital cortices. 
Movement disorders: 
 A total of 104  patients with 
Parkinsonism were evaluated on FDG 
PET/CT. Of these, F-DOPA studies were 
performed on 87 cases. Only patients who 
could be clinically followed up for at least 
one year were included in the study.  
Differentiation of various types of 
Parkinsonian syndromes was possible on 
FDG PET/CT studies.  Early untreated PD 
showed pallidothalamic hypermetabolism 
(ﬁg.5,6). Several patients also showed 
cortical hypometabolism, predominantly 
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Fig. 3 :  An advanced  case of Alzheimer's  
disease : FDG PET/CT scan shows bilateral 
temporo-parietal and frontal hypometabolism with 
sparing of occipital cortices.
Fig. 4 :  A classical case of fronto - temporal 
d e m e n t i a  :  F D G  P E T / C T  s c a n  s h o w s 
bilateral  fronto - temporal  hypometabolism.
Fig.5 :  FDG-PET/CT scan in a normal control 
(A). Note uniform metabolic activity in cerebral 
cortices and deep grey matter. The F-DOPA 
scan (B) in this healthy patient shows intense 
uptake in the basal ganglia with minimal 
activity in the cortices.
Fig.6 :  FDG-PET/CT scan in a patient with 
Parkinson's disease (A). Note the relative 
hype rme tabo l i sm  in  t he  ba sa l  gang l i a 
compared to the metabolic activity in cerebral 
cortices.  The F-DOPA scan (B) in this  patient 
shows reduced uptake in bilateral putamen 
with preserved uptake in the cerebral cortices.
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in the parieto-occipital and dorsolateral 
prefrontal  cortices.  Patients with 
progressive supranuclear palsy (PSP) 
showed hypometabolism predominantly  
in the mid-brain, basal ganglia and 
anterior cingulate cortices. Patients with 
multisystem atrophy (MSA) showed 
hypometabolism in the pons and 
dorsolateral putamen, with or without 
hypometabolism in bilateral cerebellar 
h e m i s p h e r e .  P a t i e n t s  w i t h 
corticobasalganglionic degeneration 
( C B G D )  s h o w e d  a s y m m e t r i c a l 
hypometabolism in parietal cortices and 
basal ganglia contralateral to the clinically 
more affected side. F-DOPA studies 
showed high sensitivity towards the 
detection of PD and Parkinsonian 
syndromes. Reduced uptake in the 
putamen with relatively normal uptake in 
the caudate nucleus was seen in cases of 
PD (ﬁg.5,6).  Uniformly reduced  F-
DOPA uptake was noted in both caudate 
and putamen in case of Parkinsonian 
syndromes, although DOPA could not 
help distinguish between the various 
categories of Parkinsonian syndromes.
Discussion
 PET/CT has been widely used in 
the study of various central nervous 
system disorders. A number of different 
radiopharmaceuticals labelled with 
positron emitting radioisotopes, such as 
11 18
carbon-11 ( C), ﬂuorine 18( F) and 
13
nitrogen -13 ( N) have been developed for 
measuring blood ﬂow, neurotransmitter 
systems and cerebral metabolism (6). The 
radiopharmaceutical which is most 
popularly used at present is FDG. Owing 
to certain inherent limitations of this 
radiotracer, newer agents are being used to 
study the pathological states in the brain. 
Brain tumors:
 The  novel PET radiotracers used 
for oncological applications include 
tracers for amino-acid synthesis, DNA 
synthesis, lipid synthesis, hypoxia and 
angiogenesis. Malignant transformation 
increases the use of aminoacids for 
energy, protein synthesis and cell division.  
Among the radiotracers for protein 
syn thes i s ,  11C-meth ion ine ,  3 ,4 -
dihydroxy-6-18F-ﬂuoro-L-phenylalanine 
(F-DOPA) and O-(2-[18F]ﬂuoroethyl)-l-
tyrosine (FET) have been widely studied. 
These radiotracers have proven superior 
to FDG in the evaluation of brain tumors 
as their reduced uptake in healthy brain 
tissue results in enhanced contrast 
between the brain tumor and the 
surrounding normal parenchyma (7).  
11C-methionine has proven more 
efﬁcacious than FDG PET/CT both for the 
primary detection of tumor and for 
delineation of its extent. Additionally, it 
can  d i ffe ren t ia te  tumorous  f rom 
nontumorous lesions with a high degree of 
sensitivity and speciﬁcity (8). Owing to its 
selective uptake in brain tumors, 11C 
methionine PET/CT has also been found 
to be a useful modality for assessing the 
size and margins of gliomas that may not 
enhance on contrast-enhanced Magnetic 
resonance imaging (MRI) imaging. It also 
plays an important role as a marker for cell 
proliferation and angiogenesis (9) and can 
be used to evaluate tumor grade in 
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gliomas, thus allowing better tumor 
prognosis (10). The results of our study 
corroborate with those of previous 
studies, with clear evidence of better 
tumor  de l inea t ion  and  improved 
diagnostic efﬁcacy in both primary and 
recurrent tumors . Additionally, our study 
shows that interobserver variability in 
interpretation is less on 11C-methionine 
compared to FDG.
 Owing to the short half life of 20 
minutes that 11C methionine has, its use 
has been limited to institutions with an on-
site cyclotron. Aminoacids labeled with a 
radiotracer having a longer half-life would 
be preferred in the routine clinical setting. 
Of these, F-DOPA and FET have been 
widely studied. These amino acids are 
retained in tumor cells, which exhibit 
higher metabolic activities than most 
normal cells. Our study shows that F-
DOPA has proven superior to FDG in the 
evaluation of low grade tumors, which are 
frequently FDG negative. Owing to its 
afﬁnity for low grade tumors as well, F-
DOPA may not be useful for assessing 
tumor grade.  FET PET when combined 
with MRI signiﬁcantly improves the 
identiﬁcation of cellular glioma tissue 
(11). In addition, high- and low-grade 
brain tumors can be differentiated on the 
basis of the different uptake kinetics of 
FET. It would be worthwhile to conduct a 
comparative analysis of these 3 major 
amino-acid radiotracers, namely  11C 
methionine, F-DOPA and FET.  However, 
logistical considerations and radiation 
dose to the patient need to be taken into 
account, before undertaking such studies.
 DNA synthesis is an important 
prerequisite for cellular proliferation. The 
most widely used radiotracer for assessing 
DNA synthesis is 3-deoxy-3-[18F] 
ﬂurothymidine (FLT). The imaging of 
cellular proliferation has a potential 
advantage over glucose imaging because 
FLT is speciﬁc to tumors, while high 
levels of energy metabolism are also seen 
w i t h  o t h e r  p r o c e s s e s  i n c l u d i n g 
inﬂammation(12).  Thus, unlike FDG it 
does not show uptake into inﬂammatory 
cells and has been widely used to 
distinguish benign from malignant 
pulmonary lesions. Like 11C methionine, 
the background uptake in normal brain 
parenchyma is low, thus enhancing tumor 
detection. It has been found useful for the 
differentiation of low-grade from high-
grade gliomas, but not for distinguishing 
low-grade gliomas from nonmalignant 
lesions(13). Our study shows that 
although FLT performed well in case of 
h i g h  g r a d e  g l i o m a s ,  i t   f a i r e d 
suboptimally in case of low grade gliomas 
– both in case of primary and recurrent 
tumors.  Adequate tumor vascularization 
is an important precondition to tumor 
growth. Inadequate vascularization would 
culminate in tumor hypoxia and eventual 
necrosis. Hypoxic tissue is inherently 
more resistant to chemotherapy or 
radiotherapy and this is often responsible 
for failure of chemo-radiotherapy and an 
overall poor response. Several in vivo PET 
tracers have been developed to assess 
t u m o r  h y p o x i a ,  e . g . , [ 1 8 ]  F 
ﬂuoromisonidazole  (FMISO) and 
6 4 / 6 0 C u ( I I ) - d i a c e t y l b i s  ( N - 4 -
methylthiosemicarbazone) (64/60Cu-
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accumulate in hypoxic rather than 
normoxic cells. The most extensively 
u sed  r ad io t r ace r  fo r  hypox ia  i s 
FMISO(14). Inclusion of FMISO imaging 
data provides information that is 
complementary to FDG PET data by 
correlating metabolic activity to tumor 
hypoxia. 
 The next generation of PET tracers 
includes those that will bind to speciﬁc 
cancer-related receptors or antigens (2). 
These agents would offer tremendous 
opportunities for selective imaging, thus 
increasing the sensitivity and speciﬁcity 
for a particular tumor. There would also be 
enormous potent ia l  for  direct ing 
molecular therapies targeted at these 
neoplasms. The development of targeted 
radiolabeled drugs to explore the efﬁcacy 
of anticancer regimens holds promise for 
the future.
Dementia
 With the introduction of several 
novel drugs to treat patients with 
Alzheimer's disease, accurate and early 
diagnosis is paramount to assess the type 
of therapeutic intervention.  Because the 
disease is initiated at the molecular and 
cellular level early in its course, metabolic 
imaging appears to be the modality of 
choice for screening patients with 
memory loss (15). The present study 
shows that FDG PET/CT is useful in early 
diagnosis of MCI, which is often a 
diagnostic dilemma clinically. At the early 
stages of the disease, functional imaging 
with ﬂow tracers (using PET or SPECT), 
or MR perfusion studies may not be 
sensitive enough to detect evidence of the 
disease. In advanced cases of course, 
structural changes would accompany the 
functional derangements. FDG PET/CT 
enables the evaluation of glucose 
metabolism of the brain parenchyma, 
which is usually done qualitatively or 
semiquantitatively, although absolute 
quantiﬁcation is also possible. In the 
healthy brain, cerebral blood ﬂow is 
tightly coupled with local metabolic 
needs, thus both blood ﬂow and glucose 
metabolic rate co-vary linearly. Thus, the 
pattern of distribution of the blood ﬂow 
tracer oxygen-15-labelled water closely 
parallels that of the metabolic tracer FDG 
throughout the cortical surface (15). 
Dissociations may occur in certain 
pathological circumstances. 
 PET/CT studies using FDG in the 
dementia patient, have enabled early 
detection and differentiation of the 
various forms of dementia. Our study, 
which was the ﬁrst of its kind performed 
on the Indian population, showed clear 
distinction in the patterns of glucose 
metabolism in the various subtypes, with 
hypometabolism in the mesiotemporal 
cortex in MCI, temporoparietal cortex in 
AD, frontotemporal cortex in FTD and 
diffuse involvement in DLBD. Further, a 
signiﬁcantly higher proportion of frontal 
lobe involvement was noted in AD in the 
Indian population. Regional cerebral 
metabolic changes associated with early 
AD can be detected with PET/CT even 
before the symptomatic manifestations of 
the disease become obvious. FDG 
PET/CT can also serve explicitly as a 
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prognostic tool, to determine likelihood of 
deterioration of mental status in the period 
following the time of scanning. PET thus 
has an incremental value beyond 
conventional clinical assessment. 
Movement Disorders
 PD is caused by the loss of the 
pigmented neurons in the substantia nigra 
and the locus coeruleus. It is believed that 
initially there is an upregulation of 
dopamine receptors, followed by a down-
regulation that occurs as the disease 
progresses (16). Conventional imaging 
techniques such as CT and MRI are not 
useful for detecting early disease or 
monitoring subtle changes in disease 
activity. There have been previous reports 
of FDG hypermetabolism in the basal 
ganglia in early PD (17). PD patients have 
been shown to have mild diffuse cortical 
hypometabolism compared to controls. In 
cases of dementia in association with PD, 
uniform cortical hypometabolism is 
noted.  FDG PET studies enables 
differentiation of the various Parkinsonian 
syndromes based on the differential 
pattern of uptake. In MSA, FDG uptake is 
reduced in the striatum, frontal cortex and 
cerebellum (18). As with MSA, FDG PET 
has identiﬁed hypometabolism in 
striatum, frontal cortex, thalamus and 
cerebellum in PSP (19).  The results of our 
study, performed on a large scale for the 
ﬁrst time on the Indian population, also 
show differential uptake pattern in the 
various movement disorders, with 
pallidothalamic hypermetabolism in PD, 
hypometabolism predominantly  in the 
mid-brain, basal ganglia and anterior 
c i n g u l a t e  c o r t i c e s  i n  P S P , 
hypometabolism in the pons and 
dorsolateral putamen in MSA  and 
asymmetrical hypometabolism in parietal 
cortices and basal ganglia in CBGD.
 F-DOPA plays an important role in 
the diagnosis, evaluation of disease 
progression and therapeutic monitoring of 
patients with movement disorders 
at tr ibuted to PD or Parkinsonian 
syndromes. Patients with PD demonstrate 
bilaterally reduced FD uptake in the 
putamen, with normal uptake in the 
caudate nucleus. Striatal uptake of F-
DOPA decreases in proportion to disease 
severity. Striatal uptake of F-DOPA is 
markedly reduced both in caudate and 
putamen in CBGD, PSP and MSA. The 
ﬁndings in our study, which were 
performed for the ﬁrst time in the Indian 
population, corroborated well with that 
described previously.
Conclusion                        
                                                  
 PET/CT is a powerful molecular 
imaging tool in the assessment of 
neurological disease. The use of FDG and 
n o n - F D G  n o v e l  P E T 
radiopharmaceuticals facilitates the early 
diagnosis ,  del ineat ion of  extent , 
prognostication and monitoring of 
t h e r a p e u t i c  r e s p o n s e  i n  s e v e r a l 
n e u r o p a t h o l o g i c a l  s t a t e s ,  t h u s 
s t r e n g t h e n i n g  t h e  d i a g n o s t i c 
armamentarium of the clinician in his 
quest to alleviate suffering and conquer 
disease.
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